Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SLAMF8



This biomarker is also known as:
  • B-lymphocyte activator macrophage expressed,
  • CD353,
  • BCM-like membrane protein,
  • B lymphocyte activator macrophage expressed,
  • CD353 antigen,
  • SLAM family member 8,
  • BLAME,
  • Q9P0V8,
  • SBBI42,

View in BioMuta


SLAMF8 is a membrane protein belonging to the CD2 family of cell surface proteins. This protein family is characterized by Ig domains. SLAMF8 is expressed in lymph node, spleen, thymus and bone marrow. SLAMF8 may play a role in B-lineage commitment and/or modulation of signaling through the B-cell receptor. There are two isoforms of this protein, produced by alternative splicing.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


BLAME expression was absent in HUVEC (human umbilical vein endothelial cells) and tumor endothelial cells, but expression was detected in tumor leukocytes as well as normal monocytes.

Performance Comment

SLAMF8 (BLAME) was one of 13 genes out of 50 selected for further validation in PMID:21617380. SLAMF8 (BLAME) shows its highest levels of expression in tonsil and lung tissue and therefore could be suitable for abdominal imaging.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014

Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014

Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.